Abstract: Objective The aim of this study was to investigate the short-term efficacy of different statins in treatment of patients with nonalcoholic fatty liver disease (NAFLD) and hyperlipidaemia. Methods 52 patients with NAFLD and hyperlipidaemia were encountered in our hospital between September 2019 and May 2021, and were divided into two groups, with 26 cases in each group, receiving pitavastatin or atorvastatin treatment for six months. The homeostasis model assessment-insulin resistance index (HOMA－IR) were obtained, and serum tumor necrosis factor-α ( TNF-α) , interleukin-6 (IL－6) , IL-8 and high-sensitivity C-reactive protein (hs-CRP) were detected by ELISA. The controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) were recorded by FibroTouch. Results At the end of 6 months of treatment, the HOMA-IR, total cholesterol (TC), triglyceride (TG) and low density lipoprotein cholesterol (LDL- C ) levels in the pitavastatin-treated patients were (2.1±0.5), (3.5±0.4)mmol/L, (2.4±0.3)mmol/L and (2.2±0.5)mmol/L, significantly lower than [(2.5±0.4), (4.2±1.0)mmol/L, (2.9±0.4)mmol/L and (2.9±0.7)mmol/L, respectively, P＜0.05], while serum high density lipoprotein cholesterol (HDL－C) level was (1.6±0.4)mmol/L, significantly higher than [(1.3±0.3)mmol/L, P＜0.05] in atorvastatin-treated patients; there were no significant differences respect to serum cytokine levels between the two groups(P＞0.05); the CAP in the pitavastatin-treated patients was (258.4±6.3)dB/m, much lower than [(267.7±10.2)dB/m, P＜0.05] in atorvastatin-treated patients; there was no significant difference as respect to liver parenchymal echo manifestations (P＞0.05). Conclusion The statins could alleviate insulin resistance, reduce blood lipid levels and inhibit inflammatory reactions in patients with NAFLD and hyperlipidaemia, and the administration ofpitavastatinseems promising, and warrants further investigation.

Key words: Nonalcoholic fatty liver disease, Hyperlipidaemia, Pitavastatin, Atorvastatin, Therapy